March 2002
Worldwide Biotech;Mar2002, Vol. 14 Issue 3, p3
Trade Publication
Reports on the completion of the clinical trial for drugs against Alzheimer's disease by Prana Biotechnology Ltd.


Related Articles

  • Biomarkers used to track Alzheimer's progression.  // Diagnostics & Imaging Week;9/27/2007, Vol. 10 Issue 39, p11 

    The article reports that Prana Biotechnology has completed patient enrollment in its Phase II clinical trial of PBT2 in patients with early Alzheimer's disease. PBT2 is the firm's first lead compound to be selected from its drug library of Metal Protein Attenuating Compounds, which have a unique...

  • Prana wins approval for Phase II Alzheimer's disease trial.  // PharmaWatch: CNS;Jan2012, Vol. 11 Issue 1, p4 

    The article reports on the approval of the Austin Health Research Ethics Committee on the Phase II Imaging trial testing of Prana Biotechnology Ltd. for its Alzheimer's disease drug in 2011.

  • Prana ditches Alzheimer's drug program.  // PharmaWatch: CNS;May 2005, Vol. 4 Issue 5, p5 

    Reports on the decline of shares of Prana Biotechnology after the company cancelled its development program for PBT1, clioquinol in Alzheimer's disease. Finding of unacceptably high levels of a di-iodo (toxic) form of PBT1; Company's lack of a backup compound for Alzheimer's disease, PBT2, which...

  • PRANA BIOTECH GROWS GRADUALLY, REACHING FOR ALZHEIMER'S CURE. McCrary, Ernest S. // Global Finance;Sep2001, Vol. 15 Issue 10, p12 

    Focuses on the funding for the research efforts of Prana Biotechnology to find an effective treatment for Alzheimer's disease and other neurological ailments. Discovery of the compositions of the deposits in the brains of patients who had died of the disease; Development of the antibiotic...

  • Senators Hear Pleas for More Alzheimer's Research Funding. Young, Donna // BioWorld Today;5/16/2008, Vol. 19 Issue 96, p1 

    The article reports on the efforts by lawmakers and researchers in the U.S. to help patients with Alzheimer's disease. Senator Herb Kohl, chairman of the Senate Special Committee on Aging, said legislation is underway for funding research on Alzheimer's disease. Rudy Tanzi, founder of Prana...

  • Prana Shares Soar on PBT2's Positive Data.  // Bioworld Week;3/3/2008, Vol. 16 Issue 9, p4 

    The article reports on the developments of Melbourne, Australia-based Prana Biotechnology Ltd. According to the article, the company's shares increases when the result of the Phase IIa study proved that its experimental Alzheimer's disease compound PBT2 was safe and tolerable. It reveals that...

  • Prana's Alzheimer's treatment slows disease progression in extension study.  // PharmaWatch: CNS;November 2004, Vol. 3 Issue 11, p9 

    Reports on Australian firm Prana Biotechnology's increase in stocks following the announcement that its Alzheimer's treatment slowed disease progression . Results of the phase II extension trial of the drug; PBT-1's ability to slow the expected disease progression; Disease modifying effect of...

  • Good safety results for Prana.  // Australian Life Scientist;2/26/2008, p1 

    Early results from a 78-patient safety trial are promising for Prana's Alzheimer's compound.

  • Prana Shares Soar 60% on Positive Alzheimer's Data. Young, Donna // BioWorld Today;2/27/2008, Vol. 19 Issue 39, p1 

    The article reports on an increase in shares of Prana Biotechnology Ltd. on February 26, 2008. Shares of the company rose more than 60 percent before closing at $5.59, an increase of $1.49 or 36.34 percent. The increase was attributed to Phase IIa study results showing that the firm's...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics